Shares of Oxygen Biotherapeutics (OXBT +10.9%) extend yesterday's 2.6% closing gain after the...
Shares of Oxygen Biotherapeutics (OXBT +10.9%) extend yesterday's 2.6% closing gain after the company announced on yesterday that it's completed FDA requested studies on its Oxycyte, a treatment for traumatic brain injury and other brain conditions. The company says the results were positive overall, but it will continue to conduct more studies on the treatment.
From other sites
at MarketWatch.com (Sep 15, 2014)
at CNBC.com (Jun 25, 2014)
at CNBC.com (Mar 31, 2014)
at CNBC.com (Mar 17, 2014)
at MarketWatch.com (Mar 4, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs